Musculoskeletal manifestations of lysosomal storage disorders

被引:70
作者
Aldenhoven, M. [1 ]
Sakkers, R. J. B. [2 ]
Boelens, J. [1 ]
de Koning, T. J. [3 ]
Wulffraat, N. M. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Paediat Immunol Haematol & SCT, NL-3584 EA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Paediat Orthopaed Surg, NL-3584 EA Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Metab Dis, NL-3584 EA Utrecht, Netherlands
关键词
ENZYME-REPLACEMENT THERAPY; CARPAL-TUNNEL-SYNDROME; MUCOPOLYSACCHARIDOSIS TYPE-I; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; INHERITED METABOLIC DISEASES; TYPE-1; GAUCHER-DISEASE; HURLER-SCHEIE-SYNDROME; ALPHA-L-IDURONIDASE; FABRY-DISEASE;
D O I
10.1136/ard.2008.095315
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Lysosomal storage disorders (LSDs), a heterogeneous group of inborn metabolic disorders, are far more common than most doctors presume. Although patients with a severe LSD subtype are often readily diagnosed, the more attenuated subtypes are frequently missed or diagnosis is significantly delayed. The presenting manifestations often involve the bones and/or joints and therefore these patients are frequently under specialist care by (paediatric) rheumatologists, receiving inadequate treatment. Since effective disease-specific treatments, including enzyme replacement therapy and stem cell transplantation, have become available for certain LSDs and timely initiation of these treatments is necessary to prevent the development of severe, disabling and irreversible manifestations, early diagnosis has become essential. The challenge is to raise awareness for better recognition of the presenting signs and symptoms of LSDs by all doctors who may encounter these patients, including rheumatologists.
引用
收藏
页码:1659 / 1665
页数:7
相关论文
共 83 条
[1]
The clinical outcome of Hurler syndrome after stem cell transplantation [J].
Aldenboven, Mieke ;
Boelens, FaapFan ;
de Koning, Tom F. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (05) :485-498
[2]
Agalsidase-beta therapy for advanced Fabry disease - A randomized trial [J].
Banikazemi, Maryam ;
Bultas, Jan ;
Waldek, Stephen ;
Wilcox, William R. ;
Whitley, Chester B. ;
McDonald, Marie ;
Finkel, Richard ;
Packman, Seymour ;
Bichet, Daniel G. ;
Warnock, David G. ;
Desnick, Robert J. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) :77-86
[3]
Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
[4]
Trends in haematopoietic cell transplantation for inborn errors of metabolism [J].
Boelens, Jaap Jan .
JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 (2-3) :413-420
[5]
Enzyme replacement for lysosomal diseases [J].
Brady, RO .
ANNUAL REVIEW OF MEDICINE, 2006, 57 :283-296
[6]
α-L-iduronidase and enzyme replacement therapy for mucopoly'saccharidosis I [J].
Brooks, DA .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (08) :967-976
[7]
FABRY DISEASE - IMPAIRED AUTONOMIC FUNCTION [J].
CABLE, WJL ;
KOLODNY, EH ;
ADAMS, RD .
NEUROLOGY, 1982, 32 (05) :498-502
[8]
The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease [J].
Charrow, J ;
Andersson, HC ;
Kaplan, P ;
Kolodny, EH ;
Mistry, P ;
Pastores, G ;
Rosenbloom, BE ;
Scott, CR ;
Wappner, RS ;
Weinreb, NJ ;
Zimran, A .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (18) :2835-2843
[9]
Chen S J, 1996, Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi, V37, P178
[10]
Cimaz R, 2006, CLIN EXP RHEUMATOL, V24, P196